메뉴 건너뛰기




Volumn 3, Issue 3, 2009, Pages 131-139

Comparison of tiered formularies and reference pricing policies: A systematic review

Author keywords

[No Author keywords available]

Indexed keywords


EID: 70249089381     PISSN: None     EISSN: 19112092     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (17)

References (21)
  • 1
    • 54849412261 scopus 로고    scopus 로고
    • Canadian Institute for Health Information, Ottawa: Canadian Institute for Health Information
    • Canadian Institute for Health Information. Drug expenditure in Canada 1985-2007. Ottawa: Canadian Institute for Health Information: 2008.
    • (2008) Drug expenditure in Canada 1985-2007
  • 3
    • 24944478160 scopus 로고    scopus 로고
    • What is required to evaluate the impact of pharmaceutical reference pricing?
    • Puig-Junoy J. What is required to evaluate the impact of pharmaceutical reference pricing? Appl Health Econ Health Policy. 2005; 4(2):87-98.
    • (2005) Appl Health Econ Health Policy , vol.4 , Issue.2 , pp. 87-98
    • Puig-Junoy, J.1
  • 4
    • 34347381507 scopus 로고    scopus 로고
    • Prescription drug cost sharing: Associations with medication and medical utilization and spending and health
    • Goldman DP, Joyee GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61-69.
    • (2007) JAMA , vol.298 , Issue.1 , pp. 61-69
    • Goldman, D.P.1    Joyee, G.F.2    Zheng, Y.3
  • 5
    • 0038680398 scopus 로고    scopus 로고
    • Fixed and flexible formularies as cost-control mechanisms
    • Dewa CS, Hoeh JS. Fixed and flexible formularies as cost-control mechanisms. Expert Rev Pharmacoecon Outcomes Res. 2003;3(3):303-315.
    • (2003) Expert Rev Pharmacoecon Outcomes Res , vol.3 , Issue.3 , pp. 303-315
    • Dewa, C.S.1    Hoeh, J.S.2
  • 6
    • 33847333167 scopus 로고    scopus 로고
    • Reference drug programs: Effectiveness and policy implications
    • Schneeweiss S. Reference drug programs: effectiveness and policy implications. Health Policy. 2006;81(1):17-28.
    • (2006) Health Policy , vol.81 , Issue.1 , pp. 17-28
    • Schneeweiss, S.1
  • 7
    • 0037711369 scopus 로고    scopus 로고
    • Reference pricing for drugs: Is it compatible with U.S. health care?
    • Kanavos P, Reinhardt U. Reference pricing for drugs: is it compatible with U.S. health care? Health Aff (Millwood). 2003;22(3):16-30.
    • (2003) Health Aff (Millwood) , vol.22 , Issue.3 , pp. 16-30
    • Kanavos, P.1    Reinhardt, U.2
  • 9
    • 2342635017 scopus 로고    scopus 로고
    • Ottawa: Cochrane Effective Practice and Organisation of Care Review Group
    • Cochrane EPaOofCRG. Data collection checklist. Ottawa: Cochrane Effective Practice and Organisation of Care Review Group: 2002.
    • (2002) Data collection checklist
    • EPaOofCRG, C.1
  • 10
    • 33745940233 scopus 로고    scopus 로고
    • The impact of reference pricing of cardiovascular drugs on health care costs and health outcomes: Evidence from British Columbia. Volume 2
    • Technical report. Hamilton: MacMaster University
    • Grootendorst PV, Dolovich LR, Holbrook AM, Levy AR, O-Brien BJ. The impact of reference pricing of cardiovascular drugs on health care costs and health outcomes: evidence from British Columbia. Volume 2: Technical report. Hamilton: MacMaster University: 2002.
    • (2002)
    • Grootendorst, P.V.1    Dolovich, L.R.2    Holbrook, A.M.3    Levy, A.R.4    O-Brien, B.J.5
  • 12
    • 0036207932 scopus 로고    scopus 로고
    • Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization
    • Schneeweiss S, Soumerai SB, Glynn RJ, Madure M, Dormuth C, Walker AM. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. CMAJ. 2002;166(6):737-745.
    • (2002) CMAJ , vol.166 , Issue.6 , pp. 737-745
    • Schneeweiss, S.1    Soumerai, S.B.2    Glynn, R.J.3    Madure, M.4    Dormuth, C.5    Walker, A.M.6
  • 13
  • 14
    • 0035653631 scopus 로고    scopus 로고
    • Effect of a three-tier prescription copay on pharmaceutical and other medical utilization
    • Motheral B, Fairman KA. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med Care. 2001;39(12):1293-1304.
    • (2001) Med Care , vol.39 , Issue.12 , pp. 1293-1304
    • Motheral, B.1    Fairman, K.A.2
  • 15
    • 0346041518 scopus 로고    scopus 로고
    • Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs
    • Fairman KA, Motheral BR, Henderson RR. Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs. Clin Ther. 2003;25(12):3147-3161.
    • (2003) Clin Ther , vol.25 , Issue.12 , pp. 3147-3161
    • Fairman, K.A.1    Motheral, B.R.2    Henderson, R.R.3
  • 17
    • 0642339217 scopus 로고    scopus 로고
    • Effects of a 3-tier pharmacy benefit design on the prescription purchasing behavior of individuals with chronic disease
    • Nair KV, Wolfe P, Valuck RJ, McCollum MM, Ganther JM, Lewis SJ. Effects of a 3-tier pharmacy benefit design on the prescription purchasing behavior of individuals with chronic disease. J Manag Care Pharm. 2003;9(2):123-133.
    • (2003) J Manag Care Pharm , vol.9 , Issue.2 , pp. 123-133
    • Nair, K.V.1    Wolfe, P.2    Valuck, R.J.3    McCollum, M.M.4    Ganther, J.M.5    Lewis, S.J.6
  • 18
    • 28544439412 scopus 로고    scopus 로고
    • A copayment increase for prescription drugs: The long-term and short-term effects on use and expenditures
    • Gibson TB, McLaughlin CG, Smith DG. A copayment increase for prescription drugs: the long-term and short-term effects on use and expenditures. Inquiry. 2005;42(3):293-310.
    • (2005) Inquiry , vol.42 , Issue.3 , pp. 293-310
    • Gibson, T.B.1    McLaughlin, C.G.2    Smith, D.G.3
  • 19
    • 27344453213 scopus 로고    scopus 로고
    • Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization
    • Landsman PB, Yu W, Liu X, Teutsch SM, Berger ML. Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. Am J Manag Care. 2005;11(10):621-628.
    • (2005) Am J Manag Care , vol.11 , Issue.10 , pp. 621-628
    • Landsman, P.B.1    Yu, W.2    Liu, X.3    Teutsch, S.M.4    Berger, M.L.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.